Evidence map›Paper›PMID 37833562›Full record

ArticleGene therapy2024

p53 dry gene powder enhances anti-cancer effects of chemotherapy against malignant pleural mesothelioma.

Naomi Muramatsu, Misa Ichikawa, Tomoko Katagiri, Yumi Taguchi, Takashi Hatanaka, Tomoyuki Okuda, Hirokazu Okamoto

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. pH modification of gel mobility shift improves polyplex selection In Vivo.Biochemical and biophysical research communications · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Naomi MuramatsuRandis Medical Developments Inc., Nagoya, Aichi, Japan.ORCID 0009-0003-4705-4313
Misa IchikawaStateArt Inc., Chuo-ku, Tokyo, Japan.
Tomoko KatagiriStateArt Inc., Chuo-ku, Tokyo, Japan.
Yumi TaguchiStateArt Inc., Chuo-ku, Tokyo, Japan.
Takashi HatanakaStateArt Inc., Chuo-ku, Tokyo, Japan.
Tomoyuki OkudaDepartment of Drug Delivery Research, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
Hirokazu OkamotoDepartment of Drug Delivery Research, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan. okamotoh@meijo-u.ac.jp.ORCID 0000-0001-9412-4415
Meijo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dry gene powder is a novel non-viral gene-delivery system, which is inhalable with high gene expression. Previously, we showed that the transfection of p16

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsCell Line, TumorCisplatinDNAHumansPowdersTumor Suppressor Protein p53CisplatinDNAPowdersTumor Suppressor Protein p53

Identifiers

PMID37833562
OpenAlexW4387607902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.